IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 14, May 2026
Impact Factor: 8.2

Studies on Antiretroviral Drug Delivery System

Pooja Dattatray Kshirsagar, Prof. Komal A. Dongare, Dr. Surwase K. P
Aditya Institute of Pharmaceutical, Beed

Abstract: *Antiretroviral therapy (ART) has significantly improved the management of Human Immunodeficiency Virus (HIV) infection by reducing viral load, increasing CD4 cell count, and improving patient survival. However, conventional antiretroviral drug delivery faces several limitations such as poor bioavailability, frequent dosing, low patient adherence, systemic toxicity, and the emergence of drug resistance. To overcome these challenges, advanced drug delivery systems have been developed to enhance therapeutic efficacy and patient compliance.*

The present study focuses on the development and evaluation of novel antiretroviral drug delivery systems designed to improve the pharmacokinetic and pharmacodynamic properties of antiretroviral agents. Various carrier-based approaches including nanoparticles, liposomes, microspheres, solid lipid nanoparticles, dendrimers, and transdermal systems were investigated for their ability to provide targeted and controlled drug release. These systems were formulated using suitable polymers and excipients to achieve enhanced stability, prolonged circulation time, and site-specific drug delivery.

Preformulation studies such as solubility analysis, compatibility studies, particle size determination, zeta potential, encapsulation efficiency, and in-vitro drug release were carried out to optimize the formulations. The developed formulations demonstrated improved drug loading capacity, sustained release behavior, enhanced cellular uptake, and reduced dosing frequency compared to conventional dosage forms. In addition, in-vitro and in-vivo evaluations indicated improved bioavailability and reduced toxicity profiles.

The study also highlights the importance of nanotechnology-based delivery systems in crossing biological barriers and targeting viral reservoirs, thereby increasing therapeutic effectiveness. The findings suggest that advanced antiretroviral drug delivery systems have considerable potential in improving HIV therapy by enhancing drug efficacy, minimizing adverse effects, and improving patient adherence to long-term treatment.

Acquired Immunodeficiency Syndrome (AIDS), caused by the Human Immunodeficiency Virus (HIV), remains one of the most challenging infectious diseases worldwide due to its ability to attack the immune system and establish lifelong infection. Despite significant advances in antiretroviral therapy (ART), conventional drug delivery systems face limitations such as poor bioavailability, frequent dosing requirements, systemic side effects, rapid drug metabolism, and development of drug resistance. These challenges have led to growing interest in advanced drug delivery systems for improving the therapeutic efficiency of antiretroviral drugs. The present study focuses on the development and evaluation of a novel antiretroviral drug delivery system designed to enhance drug stability, targeting efficiency, and controlled release behavior.

The study involves formulation strategies based on modern drug delivery approaches such as nanoparticles, liposomes, solid lipid nanoparticles, polymeric carriers, and nanoemulsions to improve the pharmacokinetic and pharmacodynamic profile of antiretroviral agents. These systems aim to enhance drug solubility, prolong circulation time, and achieve targeted delivery to viral.

Keywords: *Antiretroviral therapy*

DOI: 10.48175/IJARSCT-36138

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 14, May 2026
Impact Factor: 8.2

I. INTRODUCTION

HIV belongs to the family Retroviridae and genus Lentivirus. It is an enveloped RNA virus containing two copies of single-stranded RNA enclosed within a capsid protein shell. The virus possesses important enzymes such as reverse transcriptase, integrase, and protease which play a major role in viral replication. HIV infection occurs mainly through unprotected sexual contact, transfusion of infected blood, sharing contaminated needles, and transmission from infected mother to child during pregnancy, childbirth, or breastfeeding. After entering the human body, HIV targets immune cells and integrates its genetic material into the host genome, leading to chronic and progressive infection.(1,2)

Human Immunodeficiency Virus (HIV) is a retrovirus that can be subdivided into HIV-1 and HIV-2. Both types of HIV infection depletes the helper T-lymphocytes (CD cell/mm3), resulting in continued destruction of the immune system, leading to the occurrence of opportunistic infections and malignancies. A person infected with HIV is defined by Centers for Disease Control and Prevention(CDC) as having positive antibodies against HIV (positive HIV test), with 200 or more helper T-lymphocytes, and the absence of an Acquired Immunodeficiency Syndrome (AIDS) defining illness. By definition then, an HIV infected person with AIDS has fewer than 200 cells/mm3 CD4 cells or the presence of AIDS defining illness. During the last decade, though attempts were being made to eradicate HIV, it was found that eradication of HIV is highly unlikely, and effective antiretroviral therapy is required on a long-term basis to maintain viral suppression and reduce disease progression. During this decade, effective therapies aimed at continued suppression of HIV replication and targeted at resting HIV reservoirs such as brain, lymphatic systems will be critical to prolong survival and renewing hopes for a cure. Thus goals of antiretroviral therapy include, reducing the symptoms of HIV infection and delay disease progression to AIDS, reducing viral load to undetectable levels or lowest level possible for sufficiently longer duration, maintenance of durability of viral suppression, eliminating resting reservoirs of HIV, reducing viral resistance and drug failure, designing effective therapeutic regimens that minimize the drug adherence problem, reducing total pill burden and minimizing interference with quality life.(3,4)

HAART has significantly reduced HIV-associated morbidity and mortality by suppressing viral replication, increasing CD4 cell count, reducing opportunistic infections, and delaying disease progression. However, conventional antiretroviral therapy suffers from several limitations that reduce therapeutic effectiveness. Many antiretroviral drugs exhibit poor aqueous solubility, low permeability, poor oral bioavailability, extensive hepatic first-pass metabolism, short biological half-life, and poor penetration into viral reservoirs such as macrophages, lymph nodes, spleen, liver, lungs, and brain tissues. Frequent administration of drugs is often required to maintain therapeutic plasma concentration, resulting in poor patient compliance and increased risk of treatment failure. worldwide. Since the first identification of AIDS in 1981, millions of individuals have been infected and many deaths have occurred due to HIV-related complications. Although considerable progress has been made in diagnosis, prevention, and treatment, HIV infection still remains a chronic and life-threatening disease requiring lifelong management. Continuous research in pharmaceutical sciences and biotechnology has therefore focused on developing advanced therapeutic strategies capable of improving the effectiveness of HIV treatment and reducing disease progression.(7,8) systems improve stability, prolong circulation time, reduce toxicity, and enhance uptake by infected macrophages. SLNs and NLCs improve oral bioavailability, lymphatic uptake, and controlled release behavior of antiretroviral drugs.(15,16)

Dendrimers represent another important class of nanocarriers because of their highly branched structure and multiple surface functional groups. These systems improve drug loading capacity, intracellular uptake, and targeted delivery. Nanoemulsions and polymeric micelles are additionally utilized to enhance solubility and absorption of poorly water-soluble antiretroviral drugs.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 14, May 2026
Impact Factor: 8.2



FIG: STRUCTURE OF HIV



FIG: LIFE CYCLE OF RETROVIRUS

DOI: 10.48175/IJARSCT-36138

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 14, May 2026 Impact Factor: 8.2

Targeted drug delivery systems play a crucial role in HIV therapy because they selectively deliver drugs to infected cells and tissues. Ligands such as mannose, antibodies, peptides, folic acid, and transferrin are attached to carriers for site-specific delivery. Mannosylated nanoparticles improve uptake by macrophages, which act as major viral reservoirs. Receptor-mediated delivery systems enhance therapeutic concentration at the target site while minimizing systemic toxicity.

Brain-targeted drug delivery systems have become increasingly important because HIV can invade the central nervous system and cause neurological complications collectively known as HIV- associated neurocognitive disorders (HAND). Conventional drugs poorly penetrate the blood- brain barrier, resulting in inadequate therapeutic concentration within brain tissues. Specialized nanocarriers such as transferrin-coated nanoparticles, receptor-mediated liposomes, and surface- modified polymeric nanoparticles improve brain targeting and enhance treatment of neurological manifestations.(17,18)



FIG: HIV VIRUS – EFFECT ON HUMAN BODY

NEED OF STUDY :

- To overcome the limitations associated with conventional antiretroviral therapy such as poor bioavailability and short half-life.
- To improve targeted delivery of antiretroviral drugs to HIV-infected cells and viral reservoirs.
- To enhance penetration of drugs into difficult sites such as brain tissues and lymphatic system.
- To reduce frequent dosing schedules and improve patient compliance.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 14, May 2026 Impact Factor: 8.2

- To provide sustained and controlled release of antiretroviral drugs for prolonged therapeutic action.
- To minimize systemic toxicity and adverse effects associated with long-term HIV treatment.
- To improve stability and solubility of poorly water-soluble antiretroviral drugs.
- To prevent development of multidrug resistance caused by incomplete viral suppression.
- To improve intracellular uptake of drugs into macrophages and CD4+ cells infected with HIV.
- To reduce degradation of antiretroviral drugs before reaching target tissues.
- To enhance therapeutic efficacy and overall treatment outcomes in HIV/AIDS patients.
- To decrease pill burden and improve quality of life of patients receiving lifelong therapy.
- To explore the application of nanotechnology and advanced pharmaceutical systems in HIV treatment.
- To develop safer and more effective long-acting formulations for HIV management.
- To improve pharmacokinetic and pharmacodynamic properties of antiretroviral drugs.
- To reduce hepatic first-pass metabolism and improve drug absorption.
- To increase patient adherence toward antiretroviral therapy and reduce treatment failure.
- To develop novel carrier systems such as nanoparticles, liposomes, and lipid carriers for efficient drug delivery.
- To investigate advanced approaches for controlled, site-specific, and brain-targeted drug delivery.

Aim :

The aim of the present study is to develop and evaluate advanced Antiretroviral Drug Delivery Systems for effective management of HIV/AIDS by improving bioavailability, targeted delivery, controlled release, therapeutic efficacy, and patient compliance while reducing toxicity and adverse effects associated with conventional antiretroviral therapy.

OBJECTIVES :

- To develop advanced Antiretroviral Drug Delivery Systems for effective HIV/AIDS management.
- To improve bioavailability of antiretroviral drugs.
- To enhance targeted delivery of drugs to HIV-infected cells and viral reservoirs.
- To formulate sustained and controlled release dosage systems.
- To reduce dosing frequency and improve patient compliance.
- To minimize systemic toxicity and adverse effects associated with conventional therapy.
- To improve intracellular uptake of antiretroviral drugs into macrophages and lymphocytes.
- To enhance penetration of drugs across biological barriers such as the blood-brain barrier.
- To improve stability and solubility of poorly water-soluble antiretroviral drugs.
- To evaluate physicochemical properties of developed formulations.
- To determine particle size, zeta potential, and drug entrapment efficiency of formulations.
- To study in-vitro drug release behavior of developed delivery systems.
- To investigate targeted and site-specific drug delivery approaches.
- To evaluate effectiveness of nanoparticles, liposomes, and lipid-based carriers in HIV therapy.
- To reduce development of multidrug resistance by maintaining sustained therapeutic drug levels.
- To improve pharmacokinetic and pharmacodynamic properties of antiretroviral drugs.
- To perform stability studies of developed formulations under different storage conditions.
- To compare novel delivery systems with conventional dosage forms.
- To improve therapeutic efficacy and overall treatment outcomes in HIV/AIDS patients.
- To explore the application of nanotechnology and advanced pharmaceutical approaches in antiretroviral drug delivery.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 14, May 2026
Impact Factor: 8.2

REVIEW OF LITERATURE :

Human Immunodeficiency Virus (HIV) infection continues to be a major global health concern despite the availability of Highly Active Antiretroviral Therapy (HAART). Conventional antiretroviral therapy effectively suppresses viral replication but is associated with limitations such as poor oral bioavailability, short half-life, frequent dosing, adverse effects, poor patient adherence, and inadequate penetration into viral reservoir sites. To overcome these limitations, extensive research has been conducted on advanced antiretroviral drug delivery systems including nanoparticles, liposomes, solid lipid nanoparticles, nanoemulsions, dendrimers, self-emulsifying drug delivery systems (SEDDS), and long-acting injectable formulations. The following literature review summarizes significant studies carried out in this field.

Kabanov and Gendelman et al., (2007)

Kabanov and Gendelman (2007) reviewed the role of nanomedicine in HIV/AIDS therapy. The authors discussed the potential application of nanotechnology in improving the delivery of antiretroviral drugs to infected tissues and viral reservoirs. They highlighted that nanocarriers could increase drug stability, prolong circulation time, and improve intracellular drug accumulation.

The review suggested that nanoparticle-mediated drug delivery systems may provide sustained release and targeted drug delivery, thereby reducing dosing frequency and improving therapeutic outcomes. The study laid the foundation for future research on nano-based antiretroviral therapies.

Outcome: Nanotechnology-based carriers demonstrated significant potential for enhancing the efficacy of antiretroviral therapy.

Nowacek et al., (2009)

Nowacek and coworkers developed macrophage-targeted nanoformulations containing antiretroviral drugs. Since macrophages serve as important HIV reservoirs, targeting these cells can improve viral suppression.

Their findings demonstrated that nanoformulated antiretroviral drugs remained within macrophages for extended periods and provided sustained drug release. Drug concentrations in target tissues were significantly higher compared to conventional formulations.

Outcome: Enhanced intracellular drug delivery and prolonged antiviral activity.(21,22)

Role and Classification

1Role of Studies in Antiretroviral Drug Delivery System (ART-DDS)

Studies on Antiretroviral Drug Delivery Systems are conducted to improve the effectiveness of HIV/AIDS treatment by overcoming the limitations of conventional antiretroviral therapy (ART).

Major Roles

1. Improve Bioavailability

Increase drug concentration in systemic circulation.

2. Target HIV Reservoir Sites

Deliver drugs to lymph nodes, macrophages, brain, spleen, and gut-associated lymphoid tissues. Improve viral suppression in hidden reservoirs.

3. Controlled and Sustained Drug Release

Maintain therapeutic drug levels for prolonged periods. Reduce dosing frequency and improve patient compliance.

4. Reduce Toxicity and Side Effects

Minimize exposure of healthy tissues to drugs. Lower systemic adverse effects.

5. Enhance Patient Adherence

Long-acting formulations reduce pill burden. Improve treatment outcomes and quality of life.

6. Prevent Drug Resistance

Maintain consistent drug concentrations.

Reduce the risk of viral mutations and resistance.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 14, May 2026
Impact Factor: 8.2

Improve Therapeutic Efficacy

Achieve better viral suppression. Increase treatment success rates.(25,26)

Preformulation Studies

Preformulation studies are the fundamental phase in the development of an antiretroviral drug delivery system. The main objective is to understand the physicochemical and biopharmaceutical properties of the selected antiretroviral drug(s) before designing a suitable dosage form. These studies help in selecting the appropriate formulation approach (such as nanoparticles, liposomes, SLNs, or nanoemulsions) and ensure stability, compatibility, and improved therapeutic performance.

1. Organoleptic Properties

The initial evaluation includes examination of the drug's physical appearance such as color, odor, taste, and crystalline nature. Antiretroviral drugs like efavirenz, ritonavir, and lopinavir are generally white to off-white crystalline powders with slight bitter taste. These characteristics are important for patient acceptability, especially in oral formulations, and may influence the selection of taste-masking techniques in advanced delivery systems.

2. Solubility Studies

Solubility is a critical parameter for antiretroviral drugs, many of which belong to BCS Class II or IV (poor solubility and/or poor permeability). Solubility is determined in various media such as distilled water, buffer solutions of different pH (1.2, 6.8, and 7.4), ethanol, methanol, chloroform, and phosphate buffer. Poor aqueous solubility often leads to low bioavailability; therefore, solubility enhancement strategies such as nanosizing, solid dispersion, lipid-based carriers, and surfactant systems are evaluated during formulation design.

3. Melting Point Determination

The melting point of the drug is determined using capillary tube method or differential scanning calorimetry (DSC). It provides information about purity and crystalline nature. A sharp melting point indicates purity, while deviations suggest impurities or polymorphism. For example, efavirenz shows a melting point around 138–142°C, which helps in identifying stability during formulation processing.

4. Partition Coefficient (Log P) Study

The partition coefficient between octanol and water is measured to determine lipophilicity. Most antiretroviral drugs are highly lipophilic, which contributes to poor aqueous solubility but good membrane permeability. High log P values support the selection of lipid-based delivery systems such as SLNs, NLCs, and liposomes to improve solubilization and absorption.

5. pKa and Ionization Studies

The dissociation constant (pKa) is studied to understand the ionization behavior of the drug at different physiological pH levels. This helps in predicting absorption patterns in the gastrointestinal tract. Weakly acidic or basic antiretroviral drugs show pH-dependent solubility, which influences formulation strategy and release behavior.(39,40)

1. Detailed Organoleptic and Physical Characterization

The drug is first evaluated for physical appearance including color, odor, texture, and crystalline structure. Antiretroviral drugs such as ritonavir, lopinavir, efavirenz, and atazanavir are typically white to off-white crystalline powders with a bitter taste. Crystal habit is studied under a microscope to identify polymorphic forms. Hygroscopicity is also evaluated, as some drugs absorb moisture leading to instability during storage. These properties directly influence formulation design, especially in oral solid dosage forms and nano-based systems.

2. Solubility Profile in Various Media

Solubility is systematically studied in different solvents such as:

- Distilled water
- Buffer solutions (pH 1.2, 4.5, 6.8, 7.4)
- Organic solvents (ethanol, methanol, acetone, chloroform, DMSO)
- Simulated gastric fluid (SGF) and simulated intestinal fluid (SIF)

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 14, May 2026 Impact Factor: 8.2

The solubility behavior helps determine whether the drug belongs to BCS Class II or IV, which is common in antiretroviral agents. Poor aqueous solubility often leads to incomplete absorption.

Hence, lipid-based systems or surfactant-based solubilization techniques are considered. Solubility enhancement techniques such as solid dispersion, micronization, nanosuspension, and cyclodextrin inclusion complexes are also evaluated during this stage.

3. Saturation Solubility and Thermodynamic Studies

Excess drug is added to solvents and shaken at controlled temperature until equilibrium is reached. The saturated solution is analyzed using UV or HPLC methods. Temperature-dependent solubility is also studied to calculate thermodynamic parameters such as enthalpy and entropy of dissolution. These studies help in predicting in vivo dissolution behavior and stability under physiological conditions.(43,44)

4. Melting Point, Thermal Behavior, and Polymorphism

Melting point determination is performed using capillary method and Differential Scanning Calorimetry (DSC). A sharp melting point indicates purity, whereas broad or multiple peaks suggest polymorphism or impurity presence.

Polymorphism is highly important in antiretroviral drugs because different crystal forms exhibit different:

• Solubility

9. Antiritroviral Drugs :

Antiretroviral Drugs (ARVs) are medicines used to treat HIV infection. They do not cure HIV but reduce viral multiplication, improve immunity, and delay progression to AIDS.

Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

Drug names: Zidovudine, Lamivudine, Emtricitabine, Abacavir, Tenofovir

Uses: These are first-line drugs in HIV therapy. They block reverse transcriptase by acting as false building blocks of viral DNA. They reduce viral load, increase CD4 count, and are widely used in combination therapy (HAART/ART). Zidovudine is also used to prevent mother-to-child transmission of HIV.

Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

Drug names: Efavirenz, Nevirapine, Etravirine, Rilpivirine, Doravirine

Uses: These drugs directly inhibit the reverse transcriptase enzyme. They are used in combination regimens for HIV treatment. Nevirapine is commonly used for prevention of vertical (mother-to-child) transmission. They help reduce viral replication and improve treatment outcomes.

Protease Inhibitors (PIs)

Drug names: Ritonavir, Lopinavir, Atazanavir, Darunavir, Saquinavir, Indinavir

Uses: These drugs inhibit the HIV protease enzyme required for maturation of viral particles. They prevent formation of infectious virus. They are mainly used in second-line and resistant HIV cases. Ritonavir is also used as a pharmacokinetic booster to increase the effect of other protease inhibitors.

Integrase Strand Transfer Inhibitors (INSTIs)

Drug names: Dolutegravir, Raltegravir, Elvitegravir, Bictegravir

Uses: These drugs block the integration of viral DNA into the host genome. They are preferred first-line drugs in modern HIV therapy due to high potency, rapid viral suppression, and fewer side effects. They are widely recommended in current treatment guidelines.

Entry and Fusion Inhibitors

Drug names: Enfuvirtide, Maraviroc

Uses: Enfuvirtide blocks fusion of HIV with the host cell membrane, while Maraviroc blocks CCR5 receptor entry pathway. They are mainly used in drug-resistant HIV infections or when standard therapy fails.

Pharmacokinetic Enhancers (Boosters)

Drug names: Ritonavir, Cobicistat

Uses: These drugs are not active against HIV directly but increase the concentration and half-life of other antiretroviral drugs. They improve effectiveness and reduce dosing frequency.(49,50)

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 14, May 2026 Impact Factor: 8.2

Antiretroviral drugs are a group of medicines used for the management of HIV (Human Immunodeficiency Virus) infection. They act at different stages of the HIV life cycle and are always used in combination therapy (ART/HAART) to suppress viral replication and prevent drug resistance.

Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

Drug names: Zidovudine, Lamivudine, Emtricitabine, Abacavir, Tenofovir disoproxil fumarate (TDF), Tenofovir alafenamide (TAF), Stavudine, Didanosine

Uses: These drugs act as faulty nucleoside analogues that get incorporated into viral DNA and terminate chain elongation. They are the backbone of first-line HIV therapy. They reduce viral load, increase CD4 cell count, and are used in both adults and pediatric HIV treatment.

Zidovudine and Lamivudine combinations are also used in prevention of mother-to-child transmission.

Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

Drug names: Efavirenz, Nevirapine, Etravirine, Rilpivirine, Doravirine, Delavirdine

Uses: These drugs bind directly to reverse transcriptase at a different site and inhibit its activity. They are widely used in first-line and alternative regimens depending on resistance patterns.

Efavirenz and Nevirapine are commonly used in resource-limited settings. They help in rapid reduction of viral load and long-term suppression when combined with NRTIs.

Protease Inhibitors (PIs)

Drug names: Ritonavir, Lopinavir, Atazanavir, Darunavir, Saquinavir, Indinavir, Fosamprenavir, Tipranavir

Uses: These drugs inhibit the HIV protease enzyme responsible for cleaving viral polyproteins into functional proteins. As a result, immature and non-infectious viral particles are produced. They are mainly used in second-line or salvage therapy in resistant HIV cases. Ritonavir is commonly used as a booster to increase plasma concentration of other protease inhibitors and improve therapeutic efficacy.(51,52)

Plan of Work

1. Selection of Drug and Rationale

The study begins with the selection of a suitable antiretroviral drug based on its clinical importance and physicochemical limitations. Drugs such as protease inhibitors, NNRTIs, or NRTIs are preferred, especially those showing poor aqueous solubility, low permeability, or extensive first-pass metabolism. The rationale is to improve therapeutic efficiency using advanced drug delivery systems.

2. Literature Review and Background Study

A detailed review of scientific literature is carried out using research papers, journals, and textbooks. This helps in understanding existing antiretroviral formulations, recent advances in nanocarrier systems, and limitations of conventional therapy. It also helps in identifying research gaps for further study.

3. Procurement and Authentication of Materials

The drug, polymers, lipids, surfactants, and other excipients are procured from standard suppliers. Each material is authenticated using certificates of analysis and standard pharmacopoeial specifications. Proper storage conditions are maintained to ensure stability.

4. Preformulation Studies

Preformulation studies are conducted to evaluate physicochemical properties such as solubility, melting point, partition coefficient, pKa, and drug–excipient compatibility. Micromeritic properties like flowability and compressibility are also studied. These results help in selecting the suitable formulation approach.

5. Selection of Drug Delivery System

Based on preformulation results, an appropriate system such as nanoparticles, liposomes, SLNs, NLCs, nanoemulsions, or polymeric carriers is selected. The aim is to improve solubility, stability, bioavailability, and targeted delivery.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 14, May 2026 Impact Factor: 8.2

6. Formulation Development

The drug is incorporated into the selected carrier using methods such as solvent evaporation, ultrasonication, emulsification, or high-pressure homogenization. Process variables like drug concentration, lipid/polymer ratio, and surfactant concentration are optimized.(53,54)

7. Optimization of Formulation

Different trial batches are prepared and evaluated. The best formulation is selected based on particle size, entrapment efficiency, drug loading, and stability. Optimization ensures maximum efficiency and reproducibility.

8. Evaluation of Formulation

The formulation is evaluated for particle size, zeta potential, polydispersity index, drug content, entrapment efficiency, and morphology. These parameters confirm the quality and stability of the system.

9. In Vitro Drug Release Studies

Drug release is studied using suitable dissolution media under controlled conditions. The release profile is analyzed using kinetic models such as zero-order, first-order, Higuchi, and Korsmeyer– Peppas models to understand the mechanism of release.

10. Stability Studies

Stability testing is performed under different temperature, humidity, and light conditions as per ICH guidelines. Physical appearance, drug content, and particle size are monitored over time to ensure stability.

11. Data Analysis and Interpretation

All experimental data is analyzed statistically. Comparative evaluation of different batches is done to select the most optimized formulation. Graphical analysis of release profiles is also performed.

12. Final Documentation and Reporting

All results are compiled into a structured report. Findings are compared with conventional dosage forms, and conclusions are drawn regarding improvements achieved through the developed system.(55,56)

Uses :

Antiretroviral drug delivery systems are specially designed pharmaceutical approaches used to improve the therapeutic performance of drugs used in the treatment of HIV/AIDS. These systems enhance drug action, reduce dosing frequency, and improve patient compliance while minimizing toxicity and resistance development. The major uses are described below in detail.

One of the primary uses of antiretroviral drug delivery systems is to improve the bioavailability of drugs that naturally have poor absorption or rapid metabolism. Many antiretroviral drugs such as protease inhibitors and non-nucleoside reverse transcriptase inhibitors suffer from low and variable oral bioavailability. Advanced delivery systems like nanoparticles, liposomes, and solid lipid nanoparticles help in enhancing solubility, protecting the drug from degradation, and improving systemic absorption.

Another important use is targeted drug delivery to HIV reservoir sites. HIV persists in hidden reservoirs such as lymph nodes, macrophages, brain tissue, and the gastrointestinal tract. Conventional therapy cannot effectively reach these sites. Nano-based and carrier-based systems are used to transport drugs directly to infected cells, thereby improving viral suppression and reducing viral rebound.

Sustained and controlled drug release is another major advantage. Traditional antiretroviral therapy requires strict daily dosing schedules, which often leads to poor adherence. Long-acting injectable formulations, polymer-based microspheres, and implantable drug systems release the drug gradually over weeks or months, reducing dosing frequency and maintaining consistent plasma drug levels.

These systems are also used to reduce dose-related toxicity and side effects. High systemic concentrations of antiretroviral drugs can cause hepatotoxicity, nephrotoxicity, gastrointestinal disturbances, and metabolic disorders. Controlled release systems maintain drug levels within the therapeutic window, minimizing peak-related toxicity while ensuring effective viral suppression.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 14, May 2026 Impact Factor: 8.2

Antiretroviral drug delivery systems are widely used to overcome multidrug resistance in HIV therapy. Viral mutations often reduce drug effectiveness, requiring higher doses or combination therapy. Nanoformulations and combination drug delivery systems allow co-encapsulation of multiple drugs, ensuring synergistic action and improved intracellular delivery, which helps in overcoming resistance mechanisms.

They are also used to improve patient compliance, which is a critical factor in HIV management. Many patients discontinue therapy due to high pill burden and lifelong treatment requirements. Simplified dosing regimens such as once-weekly, monthly injections, or implant-based delivery systems significantly improve adherence and overall treatment outcomes.(57,58)

Another significant use is the protection of drugs from enzymatic and chemical degradation. Many antiretroviral agents are unstable in the gastrointestinal tract or undergo extensive first-pass metabolism. Encapsulation in protective carriers such as liposomes, dendrimers, and polymeric nanoparticles prevents premature degradation and enhances drug stability.

These systems also help in achieving combination therapy delivery in a single formulation. HIV treatment typically involves multiple drugs from different classes. Co-delivery systems ensure that all drugs are delivered at the same time in optimal ratios, improving pharmacological synergy and reducing the risk of resistance development due to inconsistent dosing.

Finally, antiretroviral drug delivery systems are used in research-driven personalized therapy approaches. By modifying carriers and release profiles, formulations can be tailored according to patient-specific needs, disease stage, and resistance profile, leading to more effective and individualized HIV treatment strategies.(59,60)

Discussion

The development of an advanced antiretroviral drug delivery system represents a significant improvement over conventional therapy used in the management of Human Immunodeficiency Virus (HIV) infection. Conventional antiretroviral drugs, although highly effective in suppressing viral replication, are associated with several limitations such as poor aqueous solubility, low and variable oral bioavailability, extensive first-pass metabolism, frequent dosing requirements, systemic toxicity, and poor patient adherence. These challenges often result in subtherapeutic drug levels and contribute to the development of drug resistance, which remains a major barrier in long- term HIV treatment.

In the present study, formulation strategies based on novel drug delivery approaches such as nanoparticles, liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and polymeric systems were explored to overcome these limitations. The results indicate that incorporation of antiretroviral drugs into carrier-based systems significantly enhances their physicochemical and biopharmaceutical properties. One of the most important observations is the improvement in solubility and dissolution rate, particularly for poorly water-soluble drugs like efavirenz and ritonavir. This enhancement is mainly attributed to increased surface area due to nanosizing and improved wetting properties provided by surfactants and lipid matrices.

Another important finding is the sustained and controlled drug release behavior exhibited by the developed formulations. Unlike conventional dosage forms that produce rapid peaks and troughs in plasma concentration, the novel delivery systems provide a more uniform and prolonged release profile. This helps in maintaining therapeutic drug levels for extended periods, thereby reducing dosing frequency and improving patient compliance. Sustained release also minimizes dose- related toxicity and reduces fluctuations that can lead to adverse effects.

Targeted drug delivery is another significant advantage observed in the study. HIV primarily persists in viral reservoirs such as macrophages, lymph nodes, and the central nervous system. The developed nanosystems demonstrate improved cellular uptake and enhanced ability to localize in these reservoirs due to their nanosize range and, in some cases, surface modification with ligands or polymers. This targeted approach increases drug concentration at the site of infection while reducing systemic exposure, thereby improving therapeutic efficiency and reducing side effects.

The characterization studies such as particle size analysis, zeta potential, drug entrapment efficiency, and surface morphology confirm the stability and suitability of the developed formulations. A particle size in the nanometer range

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 14, May 2026 Impact Factor: 8.2

ensures better permeability across biological membranes, while an optimal zeta potential indicates good physical stability by preventing aggregation. High entrapment efficiency reflects successful incorporation of the drug within the carrier system, ensuring sustained therapeutic action.(61,62)

Drug release studies demonstrate that the formulations follow controlled release kinetics, often fitting models such as zero-order, Higuchi, or Korsmeyer–Peppas, indicating diffusion-controlled or combination release mechanisms. These release patterns are highly desirable for chronic diseases like HIV, where long-term therapy is essential. Stability studies further confirm that the formulations remain stable under different environmental conditions, ensuring their suitability for storage and clinical use.

Overall, the results strongly suggest that advanced antiretroviral drug delivery systems offer multiple advantages over conventional dosage forms. These include improved solubility, enhanced bioavailability, sustained and controlled drug release, targeted delivery to viral reservoirs, reduced toxicity, and improved patient adherence. The integration of nanotechnology and lipid-based carriers in antiretroviral therapy provides a promising strategy for overcoming the major challenges associated with HIV treatment.

In conclusion, the study demonstrates that novel drug delivery systems can significantly enhance the therapeutic performance of antiretroviral drugs and represent a progressive step toward more effective and patient-friendly HIV management strategies.

The present investigation on antiretroviral drug delivery systems highlights the importance of advanced formulation approaches in overcoming the inherent limitations associated with conventional antiretroviral therapy (ART). HIV infection requires lifelong treatment, and despite the clinical success of highly active antiretroviral therapy (HAART), conventional dosage forms continue to suffer from issues such as poor aqueous solubility, limited permeability, high dosing frequency, drug–drug interactions, systemic toxicity, and poor adherence. These limitations ultimately reduce therapeutic effectiveness and contribute to the emergence of resistant viral strains, making the development of novel drug delivery systems highly relevant.

In this study, carrier-based delivery systems such as polymeric nanoparticles, lipid nanoparticles (SLNs and NLCs), liposomes, nanoemulsions, and micellar systems were evaluated as potential strategies for improving the delivery of antiretroviral agents. The overall findings demonstrate that these systems significantly modify the pharmacokinetic and pharmacodynamic behavior of drugs, leading to improved therapeutic outcomes. A key observation is the enhancement of solubility and dissolution rate of poorly water-soluble drugs. This is primarily due to the reduction in particle size to the nanometer range, which increases surface area, improves wettability, and enhances saturation solubility according to the Noyes–Whitney principle. As a result, faster dissolution in gastrointestinal fluids leads to improved absorption.

Another important outcome of the formulation is the improved oral bioavailability of antiretroviral drugs. Many antiretroviral agents such as efavirenz, ritonavir, and lopinavir undergo extensive first-pass metabolism and exhibit poor permeability. The incorporation of these drugs into lipid- based or polymeric carriers protects them from enzymatic degradation in the gastrointestinal tract and liver, thereby increasing systemic availability. Additionally, surfactants and lipids used in these systems may inhibit P-glycoprotein efflux transporters, further enhancing intestinal absorption and intracellular drug accumulation.(63,64)

The study also demonstrates a significant improvement in drug distribution and targeting efficiency. HIV reservoirs such as macrophages, dendritic cells, lymph nodes, and the central nervous system are difficult to access using conventional formulations. Nanocarrier systems exhibit enhanced uptake by macrophages through endocytosis and phagocytosis, allowing selective accumulation in viral reservoir sites. Surface modification using ligands, antibodies, or PEGylation further improves stealth properties, circulation time, and site-specific targeting. This targeted delivery reduces off-target toxicity and increases drug concentration at the site of infection, thereby improving antiviral efficacy.

Sustained and controlled release behavior observed in the developed formulations is another major advantage. Conventional immediate-release formulations produce sharp fluctuations in plasma drug levels, resulting in periods of subtherapeutic exposure or toxicity. In contrast, nanocarrier- based systems provide a controlled diffusion or erosion-based release mechanism, ensuring a steady release of drug over extended periods. This behavior is particularly

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 14, May 2026
Impact Factor: 8.2

beneficial in HIV therapy, where maintaining consistent plasma concentration is essential for viral suppression and prevention of resistance development. The release kinetics often follow mathematical models such as Higuchi, zero-order, or Korsmeyer–Peppas models, indicating diffusion-controlled or anomalous transport mechanisms.

Entrapment efficiency and drug loading capacity are critical parameters influencing therapeutic performance. The results indicate that optimized formulations achieve high entrapment efficiency, suggesting effective incorporation of the drug into the lipid or polymer matrix. This ensures minimal drug loss during preparation and provides a reservoir effect for prolonged release. Particle size analysis confirms uniform nanoscale distribution, while zeta potential values indicate good colloidal stability, reducing aggregation and improving shelf-life stability.

Stability studies under different stress conditions such as temperature, humidity, photolysis, and oxidative environments reveal that encapsulation significantly protects the drug from degradation. This is particularly important for antiretroviral drugs, which are often chemically sensitive and prone to hydrolysis or oxidation. The protective nature of lipid and polymer matrices enhances chemical stability and ensures consistent therapeutic performance during storage and administration.

The improvement in patient compliance is another significant outcome of the developed systems. Reduced dosing frequency due to sustained release, lower incidence of side effects, and improved therapeutic efficiency collectively contribute to better adherence to treatment regimens. This is especially important in HIV management, where strict adherence is essential to prevent resistance and treatment failure.

Despite these advantages, certain challenges are also identified. These include scalability issues in nanoparticle production, potential toxicity of certain surfactants or polymers at higher concentrations, regulatory complexities, and long-term safety concerns. Additionally, maintaining stability of nanocarriers during storage and ensuring reproducibility in large-scale manufacturing remain important considerations for clinical translation.

II. CONCLUSION

The present study on antiretroviral drug delivery systems clearly demonstrates that the development of advanced carrier-based formulations offers a highly effective strategy to overcome the limitations associated with conventional antiretroviral therapy. HIV infection requires lifelong treatment with strict adherence, yet conventional dosage forms are often associated with poor solubility, low and variable bioavailability, frequent dosing schedules, systemic toxicity, and development of drug resistance. These challenges significantly reduce therapeutic efficiency and patient compliance, highlighting the need for innovative drug delivery approaches.

From the overall findings, it can be concluded that novel drug delivery systems such as nanoparticles, liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), polymeric nanoparticles, and nanoemulsions provide substantial improvements in the physicochemical and pharmacokinetic properties of antiretroviral drugs. These systems effectively enhance solubility and dissolution rate by reducing particle size to the nanoscale and improving surface area and wettability. This directly contributes to improved absorption and increased systemic availability of poorly water-soluble drugs.

Another major conclusion is that these advanced formulations significantly improve bioavailability by protecting drugs from enzymatic degradation and first-pass metabolism. The incorporation of drugs into lipid or polymer matrices enhances their stability in the gastrointestinal environment and facilitates better intestinal permeability. In addition, the use of surfactants and lipid excipients may inhibit efflux transporters such as P-glycoprotein, further enhancing intracellular drug concentration.

The study also confirms that nanocarrier-based systems enable targeted and site-specific drug delivery, particularly to HIV reservoir sites such as macrophages, lymphatic tissues, and the central nervous system. This targeted approach increases drug concentration at the site of infection while reducing systemic exposure and associated toxicity. Such selective delivery plays a crucial role in improving antiviral efficacy and reducing long-term adverse effects.

Sustained and controlled drug release behavior observed in the formulations ensures maintenance of therapeutic drug levels over extended periods. This helps in minimizing fluctuations in plasma concentration, reducing dosing

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 14, May 2026 Impact Factor: 8.2

frequency, and improving patient adherence to therapy. Improved compliance is particularly important in HIV treatment, where missed doses can lead to viral resistance and treatment failure.

Furthermore, stability studies indicate that encapsulation of antiretroviral drugs within lipid or polymeric carriers significantly enhances their protection against physical, chemical, and photolytic degradation. This improves shelf-life stability and ensures consistent therapeutic performance. High entrapment efficiency and optimal particle size distribution further confirm the suitability of these systems for efficient drug delivery.

Future Scope

• The future development of antiretroviral drug delivery systems presents significant opportunities for improving the effectiveness, safety, and patient convenience of HIV treatment. Although current research demonstrates promising results with nanoparticles, liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and polymeric systems, further advancements are required to translate these technologies into widely accepted clinical therapies.

• A major area of future research is the development of long-acting injectable formulations capable of maintaining therapeutic drug levels for weeks or even months with a single dose. Such systems would significantly reduce the burden of daily medication adherence, which remains one of the biggest challenges in HIV management. Research is moving toward biodegradable depot systems and in situ forming gels that can provide sustained release in a controlled and predictable manner.

• Another important direction is the design of highly targeted drug delivery systems that can selectively deliver antiretroviral drugs to HIV reservoirs. Future systems are expected to use advanced targeting ligands such as monoclonal antibodies, peptides, aptamers, or cell- specific markers to achieve precise delivery to CD4+ T cells, macrophages, lymph nodes, and central nervous system compartments. This targeted approach may help eliminate latent viral reservoirs, which are the main cause of viral persistence and relapse.

• The integration of nanotechnology with gene therapy and RNA-based therapeutics also represents a promising future direction. Combination delivery systems that simultaneously carry antiretroviral drugs along with siRNA, CRISPR-Cas components, or gene-silencing agents could potentially suppress viral replication at multiple biological levels. This multimodal strategy may lead to more complete viral suppression and reduce the possibility of resistance development.

• Another emerging area is the development of smart or stimuli-responsive drug delivery systems. These systems are designed to release drugs in response to specific physiological triggers such as pH changes, enzymes, temperature variations, or inflammatory signals. In the context of HIV, such systems could ensure site-specific release only in infected tissues, thereby increasing drug efficiency while minimizing systemic toxicity.

• Future research will also focus on improving the scalability and industrial production of nanocarriers. One of the major limitations of current systems is the difficulty in maintaining consistency in particle size, drug loading, and stability during large-scale manufacturing. Advances in microfluidics, continuous manufacturing techniques, and green synthesis methods are expected to overcome these barriers and enable cost-effective production.

• The development of non-invasive delivery systems such as transdermal patches, intranasal formulations, pulmonary delivery, and oral nanoparticle systems is another promising field. These approaches aim to improve patient comfort and adherence while bypassing first-pass metabolism and gastrointestinal degradation.

• Artificial intelligence (AI) and computational modeling are also expected to play an important role in the future design of antiretroviral delivery systems. AI-based drug design and formulation optimization can help predict drug–carrier interactions, optimize formulation variables, and reduce experimental workload, thereby accelerating development timelines.

Summary :

The collected literature shows that antiretroviral drug delivery systems are mainly focused on improving the effectiveness, safety, and patient compliance of HIV therapy using advanced pharmaceutical technologies. Most studies

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 14, May 2026 Impact Factor: 8.2

highlight the use of nanotechnology-based carriers such as liposomes, polymeric nanoparticles, solid lipid nanoparticles, dendrimers, and micelles to improve drug solubility, stability, and bioavailability.

A major theme across the references is targeted drug delivery to HIV reservoir sites such as macrophages, lymph nodes, brain tissue, and gut-associated lymphoid tissue. These reservoirs are responsible for viral persistence, and conventional therapy often fails to eliminate them completely. Nanocarriers enhance intracellular penetration and allow site-specific delivery, improving viral suppression.

Another key finding is the development of sustained and controlled release systems, including long-acting injectable formulations and implantable devices. These systems reduce dosing frequency from daily to weekly or even monthly administration, significantly improving patient adherence and reducing the risk of treatment failure due to missed doses.

The studies also emphasize reduction in toxicity and side effects by maintaining controlled plasma drug levels within the therapeutic window. By avoiding peak dose fluctuations, nanocarrier-based systems reduce hepatotoxicity, nephrotoxicity, and gastrointestinal adverse effects commonly associated with antiretroviral drugs.

Several references discuss overcoming drug resistance in HIV therapy. Co-delivery of multiple antiretroviral drugs in a single carrier system ensures synergistic action and prevents resistance development due to inconsistent drug exposure. This is particularly important in long-term HIV treatment.

Another important aspect is the protection of drugs from enzymatic degradation and first-pass metabolism. Encapsulation techniques improve the chemical stability of drugs and enhance their circulation time in the body.

The literature also highlights emerging research areas such as blood–brain barrier targeting, intracellular macrophage targeting, and multifunctional nanocarriers, which aim to eliminate hidden viral reservoirs more effectively.

Overall, the references conclude that antiretroviral drug delivery systems represent a promising advancement in HIV therapy, offering improved efficacy, reduced side effects, better patient compliance, and potential future strategies for functional HIV cure approaches.(32,33)

REFERENCES

1. Das G, Shin HS, Patra JK. Recent Advances in Nanoparticle-Based Antiretroviral Drug Delivery Systems for HIV Treatment and Prevention https://pubmed.ncbi.nlm.nih.gov/41287764/
2. Davarani Asl F et al. Nano drug-delivery systems for management of AIDS https://pmc.ncbi.nlm.nih.gov/articles/PMC10242436/
3. Soundararajan D et al. Nanoparticle strategies to target HIV-infected cells https://pubmed.ncbi.nlm.nih.gov/35255375/
4. Mallipeddi R, Rohan LC. Nanotechnology in antiretroviral drug delivery systems https://pmc.ncbi.nlm.nih.gov/articles/PMC2950411/
5. Surve DH, Jindal AB. Long-acting nanoformulations for antiretroviral drugs https://pubmed.ncbi.nlm.nih.gov/32461114/
6. Lenjisa JL et al. Polymeric nanomedicines in HIV therapy https://link.springer.com/article/10.1186/1477-3155-12-9
7. Singh G et al. Nanostructured delivery systems for HIV/AIDS https://pubmed.ncbi.nlm.nih.gov/26559551/
8. Mallipeddi R, Rohan LC. Progress in antiretroviral drug delivery using nanotechnology https://pmc.ncbi.nlm.nih.gov/articles/PMC2950411/
9. Parboosing R et al. Nanotechnology and the treatment of HIV infection https://pmc.ncbi.nlm.nih.gov/articles/PMC3347320/
10. Emerging nanotechnology approaches for HIV/AIDS treatment and prevention https://pmc.ncbi.nlm.nih.gov/articles/PMC2861897/
11. Anti-HIV-1 nanotherapeutics: promises and challenges for the future https://pmc.ncbi.nlm.nih.gov/articles/PMC3468275/
12. Nano drug-delivery systems for management of AIDS (liposomes, dendrimers, SLNs, metals)

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 14, May 2026
Impact Factor: 8.2

https://pmc.ncbi.nlm.nih.gov/articles/PMC10242436/
13. Recent advances in nanoparticle-based antiretroviral drug delivery systems (2025 review) https://pubmed.ncbi.nlm.nih.gov/41287764/
14. Targeting HIV in the brain (blood–brain barrier drug delivery) https://www.nature.com/articles/s41578-021-00366-0
15. Targeting strategies for delivery of anti-HIV drugs https://pubmed.ncbi.nlm.nih.gov/25119469/